Vedolizumab Post Op Study

Summary

This is a pilot study that will determine the endoscopic recurrence of Crohn's disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative vedolizumab (Entyvio) or placebo. The investigators hypothesize that the administration of post-operative vedolizumab will decrease the endoscopic recurrence of Crohn's disease.

Timeline

Start

2018-12-01

Primary completion

2019-05-01

Completion

2019-05-01

Drugs

Indications